Central Serous Chorioretinopathy Following Intravitreal Dexamethasone Implant

Noh, Gwang Myeong; Nam, Ki Yup; Lee, Seung Uk; Lee, Sang Joon

doi:10.3341/kjo.2018.0115

Cited by 7 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic corticosteroids are acknowledged to be an independent risk factor for CSC (Nicholson et al 2018b), but other routes have also been reported in in association with CSC, such as intra-nasal, intraarticular, topical-dermal, inhaled and in some cases ocular use (Bouzas et al 2002;. There are sparse reports of CSC secondary to intravitreal corticosteroids (Imasawa et al 2005;Noh et al 2019), and only one study reporting an association between CSC and use of steroid drops (Chang et al 2015). This Taiwanese population-based study, conducted over 10 years, examined 2921 CSC patients with 17,526 matched-controls and is the only report to date suggesting an increased risk of CSC with the use of steroid eye drops (Chang et al 2015).…”

Section: Corticosteroidsmentioning

confidence: 99%

Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities

Kaye

Chandra

Sheth

et al. 2020

Progress in Retinal and Eye Research

164

216

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Corticosteroidsmentioning

confidence: 99%

Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities

Kaye

Chandra

Sheth

et al. 2020

Progress in Retinal and Eye Research

164

216

View full text Add to dashboard Cite

show abstract

“…It is possible that TA injected into the vitreous cavity affects the RPE through the neural retina, as previously reported by an in vitro study [ 17 ]. Following the introduction of dexamethasone intravitreal implant as a novel treatment option, several cases of CSC caused by this intervention have been reported [ 8 ]. A multicenter Japanese survey compared CSC in patients treated and patients not treated with steroids [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

“…Interestingly, several previous studies reported a relationship between CSC and treatment with exogenous and endogenous corticosteroids administered via different routes, including oral, intravenous, intramuscular, epidural, intraarticular, topical dermal, inhaled, ophthalmic, and after dexamethasone intravitreal implant [ 5 , 6 , 7 , 8 ]. A precise molecular mechanism underlying the steroid-induced onset of CSC is currently unknown.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and Therapeutic Challenges in a Patient with Radiation Retinopathy Complicated by Corticosteroid-Induced Central Serous Chorioretinopathy

et al. 2022

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSC) is a common chorioretinal disorder. It has been postulated that impaired retinal pigment epithelium and hyperpermeability of the choriocapillaris may be involved in the development of CSC, but the exact pathomechanism has not been established. We report an unusual case of a middle-aged man who developed CSC after triamcinolone acetonide injection for macular edema. Edema developed as a late complication of radiation retinopathy after brachytherapy for childhood retinoblastoma. Steroid treatment is an important risk factor for CSC, but the underlying causative mechanisms have not been fully elucidated. It is important to increase the awareness of this link among clinicians who prescribe exogenous corticosteroids, irrespective of the route of administration.

show abstract

“…It is well known that systemic corticosteroids can induce central serous retinopathy. The association between dexamethasone implants and central serous retinopathy has been reported [ 176 ].…”

Section: Ophthalmic Management Of Dmomentioning

confidence: 99%

Diabetic Macular Oedema Guidelines: An Australian Perspective

Yuen

Gilhotra

Dalton³

et al. 2023

Journal of Ophthalmology

View full text Add to dashboard Cite

The number of people living with diabetes is expected to rise to 578 million by 2030 and to 700 million by 2045, exacting a severe socioeconomic burden on healthcare systems around the globe. This is also reflected in the increasing numbers of people with ocular complications of diabetes (namely, diabetic macular oedema (DMO) and diabetic retinopathy (DR)). In one study examining the global prevalence of DR, 35% of people with diabetes had some form of DR, 7% had PDR, 7% had DMO, and 10% were affected by these vision-threatening stages. In many regions of the world (Australia included), DR is one of the top three leading causes of vision loss amongst working age adults (20–74 years). In the management of DMO, the landmark ETDRS study demonstrated that moderate visual loss, defined as doubling of the visual angle, can be reduced by 50% or more by focal/grid laser photocoagulation. However, over the last 20 years, antivascular endothelial growth factor (VEGF) and corticosteroid therapies have emerged as alternative options for the management of DMO and provided patients with choices that have higher chances of improving vision than laser alone. In Australia, since the 2008 NHMRC guidelines, there have been significant developments in both the treatment options and treatment schedules for DMO. This working group was therefore assembled to review and address the current management options available in Australia.

show abstract

Central Serous Chorioretinopathy Following Intravitreal Dexamethasone Implant

Cited by 7 publications

References 5 publications

Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities

Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities

Diagnostic and Therapeutic Challenges in a Patient with Radiation Retinopathy Complicated by Corticosteroid-Induced Central Serous Chorioretinopathy

Diabetic Macular Oedema Guidelines: An Australian Perspective

Contact Info

Product

Resources

About